Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2017
At a glance
- Drugs Dovitinib (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
- 24 Apr 2017 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Feb 2017 New source identified and integrated (EudraCT2011-002873-47; European Clinical Trials Database).
- 14 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016.